Amarin Supported Peer Reviewed Articles EPA Research, Case Studies, Overviews
Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, King JB, Bellows BK, Tajeu GS, Derington CG, Johnson J, Andrade K, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P.
Olshansky B, Chung MK, Budoff MJ, Philip S, Jiao L, Doyle RT Jr, Copland C, Giaquinto A, Juliano RA, Bhatt DL.
Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: results from National Health and Nutrition Examination Survey (NHANES) 2007-2014.
REDUCE-IT eligibility and preventable cardiovascular events in the US population (from the National Health and Nutrition Examination Survey [NHANES]).
The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?
A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review.
Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial).
Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: A prospective, placebo-controlled randomized trial (EVAPORATE): Interim Results
Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro.
Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro
Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography.
Risk of cardiovascular events in patients with hypertriglyceridemia: a review of real-world evidence.
Critical differences between dietary supplement and prescription omega-3 fatty acids: a narrative review.
Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dL) are significant predictors of new heart failure diagnosis: A real-world analysis of high-risk statin-treated patients.
Risk of cardiovascular events in patients with hypertriglyceridemia: a review of real-world evidence
Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk By Statin Use In U.S. Adults With Diabetes
Does High-Dose Fish Oil Reduce Cardiovascular Events Via Triglycerides?
Prevalence Of Hypertriglyceridaemia In Statin Treated Very High-Risk Patients Who Might Benefit From Treatment With Icosapent Ethyl For Secondary Prevention In Clinical Practice–Results Of DYSIS.
Association of elevated triglycerides with increased cardiovascular risk and direct costs in statin-treated patients
Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dL) are significant predictors of hospitalization for new-onset kidney disease: a real-world analysis of high-risk statin-treated patients.
Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: A large administrative retrospective analysis.
The Economic Burden of Hypertriglyceridemia Among US Adults With Diabetes or Atherosclerotic Cardiovascular Disease on Statin Therapy
The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease.
Increased residual cardiovascular risk in patients with diabetes and high vs. normal triglycerides despite statin-controlled LDL cholesterol
Comparison of medical care utilization and costs among patients with statin-controlled LDL cholesterol with versus without hypertriglyceridemia
High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk
Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol.
Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin
Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid
Cardiovascular disease and omega-3s: Prescription products and fish oil dietary supplements are not the same
Eicosapentaenoic acid as a potential therapeutic approach to reduce cardiovascular risk in patients with end-stage renal disease on hemodialysis: a review
Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits
Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes.
Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients
witching from EPA + DHA (omega-3-acid ethyl esters) to high-purity EPA (icosapent ethyl) in a statin-treated patient with persistent dyslipidemia and high cardiovascular risk: a case study
A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States.
Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements
Omega-3 fatty acid formulations in cardiovascular disease: dietary supplements are not substitutes for prescription products
Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents
Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series
Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides
Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis
Retrospective case series of patients with diabetes or prediabetes who were switched from omega-3-acid ethyl esters to icosapent ethyl
Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism
A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients
Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options
A new pure O-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial
Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review.